Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

Clinical Microbiology and Infection

Volumn 9, Issue 7, 2003, Pages 691-703

  Carbon, Claude ^a   Moola, S ^b   Velancsics, I ^c   Leroy, B ^d   Rangaraju, M ^d   Decosta, P ^d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ADDINGTON HOSPITAL   (South Africa)

^c Paracelsus Klinik Marl   (Germany)

^d NONE

Author keywords

Community acquired pneumonia; Ketolide; Pharmacokinetics; Respiratory tract infection; Telithromycin

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARDIAC GLYCOSIDE; CEFTRIAXONE; CEPHALOSPORIN; CHOLINESTERASE INHIBITOR; CISAPRIDE; CLARITHROMYCIN; DIRITHROMYCIN; ERGOT ALKALOID; ERYTHROMYCIN; KETAMINE; KETOCONAZOLE; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PIMOZIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN; TELITHROMYCIN; TERFENADINE; TETRACYCLINE; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BLOOD SAMPLING; CHLAMYDOPHILA PNEUMONIAE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; NAUSEA AND VOMITING; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCORING SYSTEM; SPUTUM; SYMPTOMATOLOGY;

BACTERIA (MICROORGANISMS); CHLAMYDOPHILA; CHLAMYDOPHILA PNEUMONIAE; LEGIONELLA; LEGIONELLA PNEUMOPHILA; MYCOPLASMA; MYCOPLASMA PNEUMONIAE;

EID: 0041525439     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00678.x     Document Type: Article

References (40)

1. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
2. Garau J. Changing patterns of etiology and resistance in community-acquired respiratory tract infections. Infect Dis Clin Pract 1998; 7 (Suppl. 2): 92-5.
3. Hammerschlag MR. Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment. Infect Dis Clin Pract 1999; 8: 232-40.
4. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 349-50.
5. Niederman MS, Bass JB Jr, Campbell JD et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148: 1418-26.
6. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11: 35-43.
7. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in the 1996-97 respiratory season. Diagn Microbiol Infect Dis 1997; 29: 249-57.
8. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-50.
9. Vesga O, Bonnat C, Craig A. In vivo pharmacodynamic activity of HMR 3647, (Abstract F-255) a new ketolide: 188. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 1997.
10. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin, four macrolides, clindamycin and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 414-7.
11. Namour F, Wessels DH, Pascual MH et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001; 45: 170-5.
12. Gia HP, Roeder V, Namour F, Sultan E, Lenfant B. The new ketolide, HMR 3647, achieves high and sustained concentrations in white blood cells in man. J Antimicrob Chemother 1999; 44 (Suppl A): 54.
13. Muller-Serieys C, Soler P, Cantalloube C et al. Broncho-pulmonary disposition of the ketolide antimicrobial telithromycin (HMR 3647). Antimicorb Agents Chemother 2001; 45: 3104-8.
14. Namour F, Sultan E, Pascual MH, Lenfant B. Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration. J Antimicrob Chemother 2002; 49: 1035-8.
15. Bhargava V, Lenfant B, Perret C et al. Lack of effect of food on the bioavailability of a new ketolide antibacterial telithromycin. Scand J Infect Dis 2002; 34: 823-6.
16. Geckler RW, Gremillion DH, McAllister CK, Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol 1977; 6: 396-9.
17. Gleckman R, DeVita J, Hibert D, Pelletier C, Martin R. Sputum Gram stain assessment in community-aquired bacteremic pneumonia. J Clin Microbiol 1988; 26: 846-9.
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard, 4th edn. NCCLS document M7-A4. Pennsylvania, USA: NCCLS, 1997.
19. Swan H, Saarinen K, Kontula K, Toivonen L, Viitasalo M. Evaluation of QT interval duration in diagnosis of long QT syndrome in patients with a genetically uniform type of LQT1. J Am Coll Cardiol 1998; 32: 486-91.
20. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
21. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (Suppl. 4): IV1-64.
22. Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000; 160: 1399-408.
23. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Cin Infect Dis 2000; 31: 383-421.
24. ERS Task Force Report. Guidelines for management of community-acquired lower respiratory tract infections. European Respiratory Society. Eur Respir J 1998; 11: 986-91.
25. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily therapy with telithromycin, the first ketolide antimicrobial, compared with high-dose amoxicillin for the treatment of community-acquired pneumonia. Infection 2002; 30: 378-86.
26. Tellier G, Hassman J, Leroy B, Sidarous E, Youngblood D. Oral telithromycin (HMR 3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community-acquired pneumonia (CAP) in adults [abstract 2227]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 2000, 471.
27. Pullman J, Champlin J, Vrooman PS, Efficacy and tolerability of once daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003 (in press).
28. van Rensburg DJ, Matthews PA, Leroy B. Efficacy and safety of telithromycin, in community-acquired pneumonia. Curr Med Res Opin 2002; 18: 397-400.
29. Fogarty C, Patel TC, Galbraith H, et al. Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of adult patients with community-acquired pneumonia caused by Streptococcus pneumoniae [abstract 857]. In: Abstracts of the, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22-25, 2001, Chicago, USA. Washington DC: American Society for Microbiology, 2001, 449.
30. Tellier G, Isakov T, Petermann W, Patel M, Lavin B. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia [abstract L-373]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, USA. Washington DC: American Society for Microbiology, 2002: 346.
31. Barman Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61: 815-29.
32. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21: 103-17.
33. Örtqvist Åvaltonen M, Cars O, Wahl M, Saikku P, Jean C and the Scandinavian Sparfloxacin Study Group. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996; 110: 1499-506.
34. Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991; 27 (Suppl. A): 117-24.
35. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl. 1): S62-88.
36. Hagberg L, Pullman J, Rangaraju M, et al. Telithromycin is effective in the treatment of pneumococcal bacteremia associated with community-acquired pneumonia [abstract 861]. In: Abstracts of the, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22-25, 2001, Chicago, USA. Washington DC: American Society for Microbiology, 2001, 450.
37. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB. Once daily sparfloxacin versus high-dose amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998; 26: 1312-20.
38. Jacobson K. Clinical efficacy of dirithromycin in pneumonia. J Antimicrob Chemother 1993; 31 (Suppl. C): 121-9.
39. Liipo K, Tala E, Puolijoki H, Brückner OJ, Rodrig J, Smits JPH. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. J Infect 1994; 28: 131-9.
40. Lode H. The experience from clinical trials with a new quinolone for community-acquired pneumonia. Eur Respir Rev 1998; 8: 299-303.